Critical analytical evaluation of promising markers for sarcopenia

Cruz-Jentoft, 2010, Sarcopenia: European consensus on definition and diagnosis, Age Ageing, 39, 412, 10.1093/ageing/afq034 Beaudart, 2015, Prevalence of sarcopenia: the impact of different diagnostic cut-off limits, Exp Gerontol, 61, 31, 10.1016/j.exger.2014.11.014 Cooper, 2013, Tools in the assessment of sarcopenia, Calcif Tissue Int, 93, 201, 10.1007/s00223-013-9757-z Beaudart, 2015, Estimation of sarcopenia prevalence using various assessment tools, Exp Gerontol, 61, 31, 10.1016/j.exger.2014.11.014 Kaji, 2014, Interaction between muscle and bone, J Bone Metab, 21, 29, 10.11005/jbm.2014.21.1.29 Kawao, 2014, Interactions between muscle tissues and bone metabolism, J Cell Biochem, 695 Elkasrawy, 2010, Myostatin (GDF-8) as a key factor linking muscle mass and bone structure, J Musculoskelet Neuronal Interact, 10, 56 Berry, 2013, Procollagen type III N-terminal peptide (P3NP) and lean mass: a cross-sectional study, J Frailty Aging, 2, 129 Lach-Trifilieff, 2014, An antibody blocking activin type ii receptors induces strong skeletal muscle hypertrophy and protects from atrophy, Mol Cell Biol, 34, 606, 10.1128/MCB.01307-13 Williams, 2004, Myostatin mutation associated with gross muscle hypertrophy in a child, N Engl J Med, 351, 1031030 Lee, 2010, Regulation of muscle mass by follistatin and activins, Mol Endocrinol, 24, 1998, 10.1210/me.2010-0127 Sanchis-Gomar, 2014, Inconsistency in circulating irisin levels: what is really happening?, Horm Metab Res, 46, 591, 10.1055/s-0033-1363283 Hecksteden, 2013, Irisin and exercise training in humans – results from a randomized controlled training trial, BMC Med, 11, 235, 10.1186/1741-7015-11-235 Stengel, 2013, Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity-Correlation with body mass index, Peptides, 39, 125, 10.1016/j.peptides.2012.11.014